Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

This study update could positively impact Vertex Pharmaceuticals and Moderna’s stock performance, as successful results may enhance their competitive position in the cystic fibrosis treatment market.

BlackDoctor.org, a health platform that reaches 20 million people, launched a new initiative, Generational Health, that aims ...

Revaccination with mRNA-1345 against RSV at 12 months was noninferior to primary vaccination among adults aged 50 years and older.

Shares of Regeneron Pharmaceuticals Inc. surged 11.82% to $654.48 Tuesday, on what proved to be an all-around positive ...

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

ResMed (RMD) is scheduled to announce Q1 earnings results on Thursday, October 30th, after market close. The consensus EPS Estimate is $2.50 (+13.6% Y/Y) and th ...

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November ...

Moderna is down 35.3% since the beginning of the year, and at $27.16 per share, it is trading 50.3% below its 52-week high of ...